shutterstock_1425740486_ii_studio
II Studio / Shutterstock.com
27 January 2020AmericasRory O'Neill

US govt PrEP patents are invalid, Gilead tells court

Gilead Sciences has accused a US government agency of withholding information from the US Patent and Trademark Office (USPTO) when filing two patents for HIV pre-exposure prophylaxis (PrEP).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
7 November 2019   The US government is suing Gilead for patent infringement, claiming that the pharmaceutical company has been piggybacking on public research to earn billions from its HIV drugs.
Americas
22 August 2019   Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.

More on this story

Americas
7 November 2019   The US government is suing Gilead for patent infringement, claiming that the pharmaceutical company has been piggybacking on public research to earn billions from its HIV drugs.
Americas
22 August 2019   Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.

More on this story

Americas
7 November 2019   The US government is suing Gilead for patent infringement, claiming that the pharmaceutical company has been piggybacking on public research to earn billions from its HIV drugs.
Americas
22 August 2019   Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.